Beam Therapeutics Inc. has appointed Eric Foster as chief commercial officer, effective immediately, to lead its commercial organization as the company prepares for the potential launch of its lead candidate risto-cel in 2027. Foster brings over 25 years of commercial leadership, most recently as chief commercial officer at Ardelyx, and previously served as senior vice president and U.S. general manager at Amgen following its acquisition of Horizon Therapeutics, where he led franchises generating $2.75 billion in net sales. CEO John Evans highlighted Foster's track record in building high-performing commercial teams in rare disease markets, which will be crucial as Beam advances multiple product candidates across its hematology and genetic disease franchises. Foster holds a Bachelor of Arts in Economics from the University of Georgia and an MBA from Auburn University.
Beam Therapeutics IncBeam appoints a chief commercial officer to lead commercialization ahead of a potential 2027 launch of risto-cel.
Amgen Inc
Ardelyx Inc